HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevalence and significance of steatorrhea in patients with active Graves' disease.

AbstractOBJECTIVE:
The aim of this study was to determine the prevalence of steatorrhea in patients with Graves' disease and to assess its significance and correlation with changes in body mass index (BMI), coefficient of fat absorption (COFA), and pancreatic exocrine function in these patients.
METHODS:
Daily dietary fat intake, 24 h fecal fat, COFA, fecal chymotrypsin activity (as an index of pancreatic exocrine function), and total T3, T4, and TSH levels were assessed in 28 patients with active Graves' disease. In 24 patients, reassessment was done after attaining a euthyroid state with carbimazole therapy.
RESULTS:
In the thyrotoxic state, 13 of 28 patients had steatorrhea, whereas 15 had normal (<6 g/day) fat excretion (11.4 +/- 6.7 g vs 2.9 +/- 0.8 g, p = 0.0007). Daily fat intake, basal BMI, and serum T3 and T4 levels were similar in the steatorrheic and nonsteatorrheic groups. The mean COFA of the steatorrheic group was significantly lower than that of nonsteatorrheic group (91.6% +/- 4.8% vs 97.7% +/- 0.9%, respectively; p = 0.0006). In the steatorrheic group, fat excretion and COFA normalized after attainment of euthyroidism (changes in fat excretion and COFA = 7.3% +/- 6.3 g/day and 7.7% +/- 5.4%, respectively). Fecal chymotrypsin levels were similar in the steatorrheic and nonsteatorrheic thyrotoxics and in 16 healthy control subjects. The levels did not show any significant changes following attainment of euthyroid status.
CONCLUSION:
Steatorrhea associated with a decrease in COFA can occur in a reversible manner in 46% of patients with Graves' disease. However, steatorrhea in these patients is not linked with weight loss or with pancreatic exocrine dysfunction.
AuthorsR Goswami, R K Tandon, A Dudha, N Kochupillai
JournalThe American journal of gastroenterology (Am J Gastroenterol) Vol. 93 Issue 7 Pg. 1122-5 (Jul 1998) ISSN: 0002-9270 [Print] United States
PMID9672342 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antithyroid Agents
  • Dietary Fats
  • Lipids
  • Triiodothyronine
  • Carbimazole
  • Thyrotropin
  • Chymotrypsin
  • Thyroxine
Topics
  • Absorption
  • Adult
  • Antithyroid Agents (therapeutic use)
  • Body Mass Index
  • Carbimazole (therapeutic use)
  • Case-Control Studies
  • Celiac Disease (complications, metabolism, physiopathology)
  • Chymotrypsin (analysis)
  • Dietary Fats (administration & dosage, pharmacokinetics)
  • Feces (chemistry, enzymology)
  • Female
  • Follow-Up Studies
  • Graves Disease (complications, drug therapy, metabolism, physiopathology)
  • Humans
  • Lipids (analysis)
  • Male
  • Pancreas (physiopathology)
  • Prevalence
  • Thyrotoxicosis (complications, metabolism)
  • Thyrotropin (blood)
  • Thyroxine (blood)
  • Triiodothyronine (blood)
  • Weight Loss (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: